Lymphomagenesis in the severe combined immune deficient mouse engrafted with human lymphocytes: Clues towards the pathogenesis and treatment of AIDS lymphoma (Review)

Oncology Reports

Volumn 4, Issue 1 SUPPL., 1997, Pages 241-246

  Khatri, Vijay P ^a   Baiocchi, Robert A ^a   Bernstein, Zale P ^a   Caligiuri, Michael A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

AIDS lymphoma; SCID mouse

Indexed keywords

INTERLEUKIN 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR XENOGRAFT;

EID: 0031017916     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Peters BS, Beck EJ, Coleman DG, Wadsworth MJH, McGuinness O, Harris JW and Pinching JJ: Changing disease patterns in patients with AIDS in a referral center in the United Kingdom: the changing face of AIDS. Br Med J 302: 203-207, 1991.
2. Bernstein L and Hamilton AS: The epidemiology of AIDS-related malignancies. Curr Opin Oncol 5: 822-830, 1993.
3. Knowles DM and Chadburn A: Lymphadenopathy and the lymphoid neoplasms associated with the acquired immune deficiency syndrome (AIDS). In: Neoplastic Hematopathology. Knowles DM (ed). Williams & Wilkins, Baltimore, 1992.
4. Meeker TC, Shiramizu B, Kaplan L, Herndier B, Sanchez H, Grimaldi JC, Baumgartner J, Rachlin J, Feigal E, Rosenblum MN and McGrath MS: Evidence for molecular subtypes of HIV associated lymphoma: division into peripheral monoclonal, polyclonal, and central nervous system lymphoma. AIDS 5: 669-674, 1991.
5. McMahon EME, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC and Ambinder RF: Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet 338: 969-973, 1991.
6. Pelicci PG, Knowles DM, Arlin Z, Wieczorek R, Luciw P, Dina D, Basilico C and Dalla-Favera R: Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in AIDS-related lymphoproliferative disorders: implications for lymphomagenesis. J Exp Med 164: 2049-2060, 1986.
7. + T-cell subsets. Immunol Rev 123: 5-22, 1991.
8. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549, 1993.
9. Hsieh CS, Heimberger AB, Gold J, O'Garra A and Murphy K: Differential regulation of T helper phenoype development by interleukins-4 and 10 in an αβ T cell-receptor transgenic system. Proc Natl Acad Sci USA 89: 6065-6069, 1992.
10. + T-helper cell subsets. Curr Opin Immunol 5: 391-397, 1993.
11. Karp JE and Broder S: Acquired immunodeficiency syndrome and non-Hodgkin's lymphomas. Cancer Res 51: 4743-4756, 1991.
12. Levine AM: Acquired immunodeficiency syndrome-related lymphoma. Blood 80: 8-20, 1992.
13. Bosma G, Custer R and Bosma M: A severe combined immuno-deficiency mutation in the mouse. Nature 301: 527-530, 1983.
14. Mosier DE: Adoptive transfer of human lymphoid cells to severely immunodeficient mice: models for normal human immune function, autoimmunity, lymphoagenesis, and AIDS. In: Advances in Immunology. Academic Press, New York, NY, pp303-325, 1991.
15. Rowe M, Young LS, Crocker J, Stokes H, Henderson S and Rickinson AB: Epstein-Barr virus (EBV)-associated lympho-proliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173: 147-158, 1991.
16. Shibata D, Weiss LM, Hemandez AM, Nathwani BN, Bernstein L and Levine AM: Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus. Blood 81: 2102-2109, 1993.
17. Veronese ML, Veronesi A, D'Andrea E, Del Mistro A, Indraccolo S, Mazza MR, Mion M, Zamarchi R, Menin C, Panpzzo M, Amadori A and Chieco-Bianchi L: Lympho-proliferative disease in human peripheral blood mononuclear cell-injected SCID mice. 1. T lymphocyte requirement for B cell tumor generation. J Exp Med 176: 1763-1767, 1992.
18. Fauci AS: Multifactoral nature of human immunodeficiency virus disease: implications for therapy. Science 262: 1011-1018, 1993.
19. Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, Sekaly RP and Fauci AS: Constitutive lack of evidence for dichotomy of Th1 and Th2 predominance in HIV-infected individuals. Science 265: 248-252, 1994.
20. Rickinson AB: Cellular immunological responses to the virus infection. In: The Epstein-Barr Virus, Recent Advances. Epstein MA and Achong BG (eds). Wiley Medical Publications, NY, 1990.
21. Baiocchi RA and Caligiuri MA: Low-dose interleukin-2 prevents the development of Epstein-Barr virus (EBV)-associated lympho-proliferative disease in seid/seid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci USA 91: 5577-5581, 1994.
22. Hill AB, Lee SP, Haurum JS, Murray N, Yao QY, Rowe M, Signoret N, Rickinson AB and McMichael AJ: Class I major histocompatibility complex-restricted cytotoxic T lymphojcytes specific for Epstein-Barr virus (EBV) nuclear antigens fail to lyse the EBV-transformed B lymphoblastoid cell lines against which they were raised. J Exp Med 181: 2221-2228, 1995.
23. Howard M and O'Garra A: Biological properties of interleukin-10. Immunol Today 13: 198-200, 1992.
24. Burdin N, Peronne C, Banchereau J and Roussel F: Epstein-Barr virus transformation induces B lymphocytes to produce human IL-10. J Exp Med 177: 295-304, 1993.
25. Baiocchi RA, Ross ME, Tan JC, Chou CC, Sullivan L, Haldar S, Monne M, Seiden MV, Narula SK, Sklar, Croce CM and Caligiuri MA: Lymphomagenesis in the SCID-human mouse involves abundant production of human interleukin-10. Blood 85: 1063-1074, 1995.
26. Fiorentino DF, Bond WB and Mosmann TR: Two types of mouse T helper cell: IV Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170: 2081-2095, 1989.
27. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M and Trinchieri G: Interleukin-10 inhibits human lymphocyte Interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178: 1041-1048, 1993.
28. Bernstein Z, Porter M, Could M, Lipman B, Bluman E, Stewart C, Hewitt RG, Fyfe G, Poiesz B and Caligiuri MA: Prolonged administration of low dose interleukin-2 in HIV-associated malignancy results in selective expansion of innate immuno effectors without significant clinical toxicity. Blood 86: 3287-3294, 1995.